Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 2
1998 1
1999 1
2000 2
2001 1
2002 3
2003 1
2004 2
2005 4
2006 7
2007 3
2008 3
2009 6
2010 2
2011 6
2012 12
2013 17
2014 23
2015 33
2016 54
2017 60
2018 49
2019 45
2020 75
2021 71
2022 60
2023 18
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 26212868

496 results

Results by year

Filters applied: . Clear all
Page 1
Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
Berenguer J, Gil-Martin Á, Jarrin I, Montes ML, Domínguez L, Aldámiz-Echevarría T, Téllez MJ, Santos I, Troya J, Losa JE, Serrano R, De Guzmán MT, Calvo MJ, González-García JJ; Madrid-CoRe Study Group. Berenguer J, et al. AIDS. 2019 Mar 15;33(4):685-689. doi: 10.1097/QAD.0000000000002103. AIDS. 2019. PMID: 30829744
Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
Pradat P, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat'AIDS study Group. Pradat P, et al. J Infect. 2017 Sep;75(3):234-241. doi: 10.1016/j.jinf.2017.05.008. Epub 2017 Jun 2. J Infect. 2017. PMID: 28579302
Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S, Martinello M, Yee J, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle JS, Shaw D, Hellard M, Petoumenos K, Carson J, Dore GJ, Matthews GV; CEASE study team. Hosseini-Hooshyar S, et al. AIDS. 2020 Jul 15;34(9):1347-1358. doi: 10.1097/QAD.0000000000002562. AIDS. 2020. PMID: 32590433
Hepatitis C reinfection after sustained virological response.
Midgard H, Bjøro B, Mæland A, Konopski Z, Kileng H, Damås JK, Paulsen J, Heggelund L, Sandvei PK, Ringstad JO, Karlsen LN, Stene-Johansen K, Pettersson JH, Dorenberg DH, Dalgard O. Midgard H, et al. J Hepatol. 2016 May;64(5):1020-1026. doi: 10.1016/j.jhep.2016.01.001. Epub 2016 Jan 11. J Hepatol. 2016. PMID: 26780289 Clinical Trial.
496 results